Alka Sachdeva, MD
Internal Medicine · Raleigh, NCNPI 1265441950
Payments from drug & device makers
Across 216 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$967
- Abbott$659
- Lilly USA, LLC$405
- AbbVie$254
- Amgen$249
- GSK$238
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,950100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $967 |
| Abbott | 42 | $659 |
| Lilly USA, LLC | 24 | $405 |
| AbbVie | 12 | $254 |
| Amgen | 17 | $249 |
| GSK | 13 | $238 |
| AstraZeneca | 14 | $210 |
| Pfizer | 5 | $155 |
| Boehringer Ingelheim | 6 | $123 |
| Exact Sciences | 5 | $103 |
| Merck | 5 | $76 |
| Astellas Pharma US Inc | 4 | $73 |
| Radius Health, Inc. | 2 | $49 |
| Lifescan, Inc. | 2 | $46 |
| Dexcom, Inc. | 2 | $44 |
| Medtronic(2 entities) | 2 | $44 |
| Amneal Pharmaceuticals LLC | 2 | $43 |
| Eisai Inc. | 2 | $31 |
| BETA Bionics, Inc. | 1 | $25 |
| Bayer | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Novartis | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$125
How this compares
$3,950 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 54 | $67,869 |
| OzempicSemaglutide | 46 | $57,408 |
| JardianceEmpagliflozin | 62 | $51,211 |
| EliquisApixaban | 22 | $38,246 |
| MounjaroTirzepatide | 30 | $32,325 |
| XareltoRivaroxaban | 25 | $29,476 |
| TrulicityDulaglutide | 21 | $29,213 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $18,128 |
| FarxigaDapagliflozin Propanediol | 13 | $17,419 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $12,493 |
| Repatha SureclickEvolocumab | 11 | $11,878 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $7,395 |
| SynthroidLevothyroxine Sodium | 50 | $5,290 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 20 | $4,192 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 13 | $3,852 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $967 | $125,277100 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $405 | $62,81863 claims |
| Boehringer IngelheimJardiance | $123 | $51,21162 claims |
| PfizerEliquis, Abrysvo | $155 | $42,09935 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $238 | $34,81360 claims |
| AstraZenecaFarxiga | $210 | $17,41913 claims |
| MerckJanumet Xr | $76 | $7,39511 claims |
| AbbVieSynthroid | $254 | $5,29050 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $43 | $2,986255 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Raleigh
- John RubinoRaleigh$13M
- Wayne HarperRaleigh$6.7M
- Bhakti PaulRaleigh$536K
- Clifford CurtisRaleigh$376K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.